Safety and Efficacy of an Intrastromal Transform Corneal Allograft (TCA) for Presbyopia Correction - Long Term Follow-up

NCT ID: NCT06310252

Last Updated: 2024-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-13

Study Completion Date

2024-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical study is to evaluate the long term safety and effectiveness of intrastromal implantation of the Allotex TransForm corneal allograft (TCA) for providing near vision in presbyopic subjects.

A maximum of 101 eyes of qualified and consented subjects will undergo long term follow-up after instrastromal implantation of the TCA for presbyopia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opthalmic assessments

The participants will undergo the following assessments:

1. Pupil size measurement
2. Manifest refraction (no autorefraction)
3. Monocular in both eyes and binocular uncorrected visual acuity (photopic):

* Distance (4 m)
* Intermediate (80 cm)
* Near (40 cm)
4. Monocular best corrected visual acuity (photopic):

* Distance (4 m)
* Near (40 cm)
* Distance-corrected near (40 cm)
5. Monocular and binocular mesopic (with and without glare) and photopic (without glare) contrast sensitivity testing (subgroup)
6. Slit lamp examination
7. Tear breakup time
8. Placido Corneal topography, keratometry and pachymetry
9. Optical coherence tomography including epithelium mapping (subgroup)
10. Applanation intraocular pressure
11. Cycloplegic refraction
12. Dilated fundus examination
13. Wavefront aberrometry (subgroup)
14. Adverse events

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide informed consent, have signed the written informed consent form, and been given a copy.
* Subjects must be willing and able to return for one scheduled follow-up examinations.
* Subjects must have undergone implantation with the TCA under study protocol PRO-010 between April 24, 2019 and October 31, 2019.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allotex, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gemini - Oční klinika Zlín

Zlín, , Czechia

Site Status

Wellington Eye Clinic

Dublin, , Ireland

Site Status

Medipol University

Istanbul, , Turkey (Türkiye)

Site Status

Centre For Sight

East Grinstead, , United Kingdom

Site Status

Eye Clinic London

London, , United Kingdom

Site Status

Centre For Sight

London, , United Kingdom

Site Status

Centre For Sight

Oxshott, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia Ireland Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO_010-2023

Identifier Type: -

Identifier Source: org_study_id